Abstract:The majority of neuro cancer research focuses on glioblastoma. BMSC-loaded miR-146b, miR-124a, miR-584, miR-133b, and miR-199a cause glioblastoma cell death by inducing apoptosis. These cancers have also been studied, but the number of studies is less than that of glioblastoma.Research into mental illness, renal injury, fibrosis, SCI, and stroke takes precedence over cancer research.MI is a well-researched disease model. miR-21, miR-132, miR-21a-5p, miR-125b, miR-214, miR-301, and miR-133 demonstrate cardioprotective properties according to these studies. miR-199a-5p, miR-486, miR-10, and miR-199a-3p suppressed the ER stress proteins and apoptotic proteins, reducing renal cell death from I/R. The use of miRNA-loaded BMSC EVs in the aforementioned fibrosis models was also proven. The research suggests that BMSC-derived EVs loaded with the aforementioned microRNAs have beneficial effects on ischemic and hemorrhagic stroke models. In SCI models, miR-133b, miR-29b, miR-21, miR-25, and miR-544 have been found to assist neural regeneration. Comparing these studies is difficult due to their complexity. These variables can be broken down as follows: Some studies only in vitro or in vivo studies, different cell lines or in vivo disease models were used in the studies, there were insufficient studies in some disease models, and different miRNAs determined by bioinformatics methods were used in each study. miRNA-derived BMSC-derived EVs are cell-free medication delivery approaches in a range of illness types. The technique employs bioinformatics analysis to find miRNAs that are downregulated in a disease model and/or miRNAs that target increased proteins in a particular signaling pathway. Electrical vehicles offer several benefits over cell-based transplantation and non-biological medication delivery technologies. To study the efficacy of this approach, there are no clinical trial investigations. A scarcity of immunogenicity and toxicity studies in these studies could hold back this method from going into clinical trials. It may be because EVs aren't intended for certain tissues or organs. Various strategies for EV membrane protein alterations and the creation of decorated EVs for cell-specific targeting have been devised. This is just a subset of the approaches available for targeted drug delivery. RVG/Lamp2b decorated EVs for nerve cell targeting can be mentioned. Additionally, superparamagnetic iron oxide nanoparticle modification of EV surfaces, chemical ligand assembly on exosomal surfaces, and pH gradient/surface charge-driven targeting may increase the efficacy of miRNA-loaded EV applications.

Delivery of therapeutic RNA by extracellular vesicles derived from Saccharomyces cerevisiae for Medicine Applications

Enhanced Extracellular Vesicle Cargo Loading via microRNA Biogenesis Pathway Modulation

Efficient RNA drug delivery using red blood cell extracellular vesicles

MicroRNA Nano-Shuttles: Engineering Extracellular Vesicles as a Cutting-Edge Biotechnology Platform for Clinical Use in Therapeutics

Engineering Extracellular Vesicles as Delivery Systems in Therapeutic Applications

Engineered mesenchymal stem cell-derived extracellular vesicles constitute a versatile platform for targeted drug delivery

Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source

Therapeutic potential of RNA-enriched Extracellular Vesicles 1: The next generation in RNA delivery via biogenic nanoparticles

Extracellular vesicles: Emerging tools as therapeutic agent carriers

Nucleolin-targeted Extracellular Vesicles as a Versatile Platform for Biologics Delivery to Breast Cancer

Extracellular Vesicles as Delivery Systems in Disease Therapy

Gene therapy using extracellular vesicles loaded with miRNA derived from Bone Marrow Mesenchymal Stem Cells is a cell-free medication delivery method used in a variety of diseases

Efficient and highly reproducible production of red blood cell-derived extracellular vesicle mimetics for the loading and delivery of RNA molecules

New Origins of Yeast, Plant and Bacterial-Derived Extracellular Vesicles to Expand and Advance Compound Delivery

Bioengineered Mesenchymal-Stromal-Cell-Derived Extracellular Vesicles as an Improved Drug Delivery System: Methods and Applications

Enhanced plant-derived vesicles for nucleotide delivery for cancer therapy

Extracellular Vesicles as Delivery Vehicles for Therapeutic Nucleic Acids in Cancer Gene Therapy: Progress and Challenges

Extracellular Vesicles in Therapeutics: A Comprehensive Review on Applications, Challenges, and Clinical Progress

Engineering therapeutical extracellular vesicles for clinical translation

Extracellular Vesicle Spherical Nucleic Acids

Targeted therapy using engineered extracellular vesicles: principles and strategies for membrane modification